Résultats de la recherche - Yin‐Miao Chen
- Résultat(s) 1 - 10 résultats de 10
-
1
-
2
-
3
Treatment with pasireotide LAR normalizes prolactin levels in patients with acromegaly and hyperprolactinemia: randomized, double-blind, 12-month, phase III study par Annamaria Colao, Pamela U. Freda, Feng Gu, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Marcello D. Bronstein
Publié 2013Artigo -
4
-
5
Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study par William J. Gradishar, Luís Meza, Bipinkumar Amin, Dvorit Samid, Todd Hill, Yin-Miao Chen, Elyse E. Lower, P. Kelly Marcom
Publié 2004Artigo -
6
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multic... par Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda, Omar Serri, Laura De Marinis, Luciana Ansaneli Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Colao
Publié 2014Artigo -
7
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-b... par Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda, Omar Serri, Laura De Marinis, Luciana Ansaneli Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Colao
Publié 2015Errata/Corrigenda -
8
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study par Marcello D. Bronstein, Maria Fleseriu, Sebastian Neggers, Annamaria Colao, Michael C. Sheppard, Feng Gu, Chiung‐Chyi Shen, Mônica R. Gadelha, Andrew J. Farrall, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Pamela U. Freda
Publié 2016Artigo -
9
Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III st... par Pamela U. Freda, Maria Fleseriu, der Lely Aart Jan van, Annamaria Colao, Michael C. Sheppard, Feng Gu, Chiung‐Chyi Shen, Mônica R. Gadelha, Andrew J. Farrall, Resendiz Karina Hermosillo, Matthieu Ruffin, YinMiao Chen, Marcello D. Bronstein
Publié 2013Artigo -
10
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial par Maria Teresa Voso, Richard A. Larson, Dan Jones, Guido Marcucci, Thomas W. Prior, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep Nomdedéu, Susan M. Geyer, Alison Walker, Andrew H. Wei, Jorge Sierra, Miguel Á. Sanz, Joseph Brandwein, Theo M. de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Sergio Amadori, Yuan Cheng, Yin-Miao Chen, Céline Pallaud, Ling Du, Alfonso Piciocchi, Gerhard Ehninger, John C. Byrd, Christian Thiede, Konstanze Döhner, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield, Francesco Lo‐Coco
Publié 2020Artigo
Outils de recherche:
Sujets similaires
Internal medicine
Medicine
Acromegaly
Growth hormone
Hormone
Pasireotide
Endocrinology
Pathology
Alternative medicine
Gastroenterology
Octreotide
Placebo
Somatostatin
Surgery
Adverse effect
Breast cancer
Cancer
Crossover study
Double blind
Logistic regression
Oncology
Urology
Aspiration pneumonia
Biochemistry
Biology
Bivariate analysis
Bone disease
Brush
Capecitabine
Chemotherapy